RELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of, U.S. Provisional Application Nos. 62/341,517, filed May 25, 2016; and 62/373,720, filed August 11, 2016; the entire contents of each of which are incorporated herein by reference in their entireties.

FIELD OF THE DISCLOSURE

[0002] The present disclosure relates to compositions and methods of treating an anxiety disorder in a patient.

BACKGROUND

[0003] Anxiety disorders are a category of mental disorders that share features of excessive fear and anxiety and related behavioral disturbances. Different anxiety disorders have distinct symptom profiles, and major types include: generalized anxiety disorder (GAD), anxiety attacks (panic disorder), obsessive-compulsive disorder (OCD), phobia, social anxiety disorder, and post-traumatic stress disorder (PTSD).

[0004] Collectively, anxiety disorders are among the most common mental disorders in the United States, with a 12-month prevalence in the U.S. adult population of about 18%, and about 4% of the U.S. adult population having an anxiety disorder classified as being severe. (http://www.nimh.nih.gov/health/statistics/prevalence/any-an xiety-disorder-among

adults. shtml). Anxiety disorders are also a common health problem globally - results of a recent survey indicate that clinical anxiety affects about 10 percent of people in North

America, Western Europe and Australia/New Zealand and about 8 percent in the Middle East and 6 percent in Asia. (Baxter, A.J. et al., Global prevalence of anxiety disorders: a

systematic review and meta-regression. Psychol. Med. 2013 43:897-910.

[0005] Patients with anxiety disorders typically experience a combination of physical, emotional, cognitive and behavioral symptoms. A number of different medications are currently used to treat one or more symptoms of anxiety disorders. Since many people diagnosed with an anxiety disorder also suffer from depression, antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are frequently used. Other medicines used to treat anxiety disorders Attorney Docket No. : MNRV-015/001 WO include: anti-anxiety medications, such as benzodiazepines, which can help reduce the symptoms of anxiety panic attacks, or extreme fear and worry; and beta-blockers, such as propranolol and atenolol, which can be useful to control physical symptoms of anxiety such as rapid heartbeat, shaking, trembling and blushing in anxious situations. However, none of the currently used medications have optimal efficacy and side effect profiles.

[0006] There remains a need to identify additional medicaments and methods that offer the potential for improved efficacy and/or lower side effects in the treating the symptoms of anxiety disorders. SUMMARY

[0007] The present disclosure is based on clinical data showing that a hydrochloride salt of the compound of formula I (Compound I),

reduced anxiety symptoms compared to placebo in a cohort of adult subjects with major depressive disorder (MDD) as measured by change from Baseline in the Hamilton Anxiety Rating Scale (HAM- A) over 6 weeks of treatment. The HAM-A Scale is described in Hamilton M: The assessment of anxiety states by rating. British Journal of Medical

Psychology. 32:50-55, 1959.

[0008] This hydrochloride salt of Compound I, having the chemical designation (2S)-l -[4- (3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l ,3,4-oxadiazol-2-yl)benzo[/)]furan-4- yloxy]propan-2-ol monohydrochloride, is named MIN-1 17 (formerly known as SON-117 and Wf-516) and is under clinical development by Minerva Neurosciences (Waltham, MA) for the treatment of major depressive disorder (MDD). The MIN-117 drug substance is an enantiomer with the (2S) configuration, a molecular formula of C25H25C12N3O4 HCI and a molecular weight of 538.85. This investigational agent has been described as behaving as an

2

145084509 vl Attorney Docket No. : MNRV-015/001 WO antagonist on 5-HTIA and 5-HT2A receptors and both serotonin and dopamine reuptake, as well as having affinity for the aiA- and aiB-adrenergic receptors (Minerva Neurosciences, Inc., Form 10K, 14 March 2016).

[0009] The compound of formula II (Compound II) is a main metabolite of MIN-117 (Ml):

The chemical name for Compound II is (25)-l-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2- (5-hydroxymethyl-l,3,4-oxadiazol-2-yl)benzo[/)]furan-4-yloxy ]propan-2-ol. The compounds of formula I and II have similar receptor and affinity binding profiles, and it is expected that the compounds of formula I and II will have similar exposures when administered to human subjects suffering from an anxiety disorder. Thus, it is expected that a compound of formula II, e.g., an isolated Compound II or a pharmaceutically acceptable salt, hydrate or solvate thereof, will produce reductions in anxiety symptoms in such subjects at similar doses as found useful for MIN-117. Unless otherwise specified, in the compositions, methods, or uses disclosed herein, Compound II or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is in an isolated form, e.g., a purified form.

[0010] In one aspect, the disclosure provides a composition comprising a compound of formula I (Compound I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder wherein the method comprises orally administering to the subject a therapeutically effective amount of the composition.

[0011] In another aspect, the disclosure provides a composition comprising a compound of formula II (Compound II), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder wherein the method comprises orally administering to the subject a therapeutically effective amount of the composition.

[0012] In an embodiment, the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of: about 0.1 mg to less than

3

145084509 vl Attorney Docket No. : MNRV-015/001 WO

3 mg, about 0.2 mg to about 2.9 mg, about 0.3 mg to about 2.8 mg, about 0.4 mg to about 2.7 mg, about 0.5 mg to about 2.6 mg, about 0.6 mg to about 2.5 mg, about 0.4 mg to about 0.6 mg and about 0.5 mg.

[0013] In another embodiment, the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of: about 0.1 mg to about 2.5 mg, about 0.1 mg to about 1 mg, about 0.1 mg to about 0.75 mg, about 0.25 to about 0.75 mg and about 0.45 mg to about 0.55 mg.

[0014] In another embodiment, the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of: about 0.1 mg to about 2.0 mg; about 0.1 mg to about 1.0 mg; and about 0.1 mg to about 0.5 mg.

[0015] In another aspect, the disclosure provides a method of treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises administering to the subject a therapeutically effective amount of Compound I, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

[0016] In another aspect, the disclosure provides a method of treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises administering to the subject a therapeutically effective amount of Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

[0017] In an embodiment, the therapeutically effective amount of Compound I or

Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, is administered orally in a total daily dose of Compound I or Compound II selected from the group consisting of: about 0.1 mg to less than 3 mg; about 0.2 mg to about 2.9 mg; about 0.3 mg to about 2.8 mg, about 0.4 mg to about 2.7 mg; about 0.5 mg to about 2.6 mg; about 0.6 mg to about 2.5 mg; about 0.4 mg to about 0.6 mg; and about 0.5 mg.

[0018] In another embodiment, the therapeutically effective amount of Compound I or Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, is administered orally in a total daily dose of Compound I or Compound II selected from the group consisting of: about 0.1 mg to about 2.5 mg; about 0.1 mg to about 1 mg; about 0.1 mg to about 0.75 mg; about 0.25 to about 0.75 mg; and about 0.45 mg to about 0.55 mg.

[0019] In another embodiment, the therapeutically effective amount of Compound I or Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, is administered orally in a total daily dose selected from the group consisting

4

145084509 vl Attorney Docket No. : MNRV-015/001 WO of: about 0.1 mg to about 2.0 mg; about 0.1 mg to about 1.0 mg; and about 0.1 mg to about 0.5 mg.

[0020] In another aspect, the subject treated with the above composition or method of the disclosure has been diagnosed with a co-morbid mental disorder. In one embodiment, the co- morbid mental disorder is a depression-related mood disorder. In another embodiment, the co-morbid mental disorder is Major Depressive Disorder (MDD).

[0021] In another aspect, the subject treated with the above composition or method of the disclosure has not been diagnosed with a depression-related mood disorder.

[0022] In some embodiments of any of the above aspects of the disclosure, the anxiety disorder is selected from the group consisting of: Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic Disorder, Panic Attack Specifier, Agoraphobia, Generalized Anxiety Disorder, Substance/Medication- Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical Condition, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, Obsessive-Compulsive Disorder (OCD), Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-Picking) Disorder, Substance/Medication-Induced Obsessive- Compulsive and Related Disorder, Obsessive-Compulsive and Related Disorder Due to Another Medical Condition, Other Specified Obsessive-Compulsive and Related Disorder, Unspecified Obsessive-Compulsive and Related Disorder, Reactive Attachment Disorder, Disinhibited Social Engagement Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorders, Other Specified Trauma- and Stressor-Related Disorder, Unspecified Trauma- and Stressor-Related Disorder. In an embodiment, the subject is diagnosed with one of these anxiety disorders based on the criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric

Association (DSM). In an embodiment, the DSM is the fourth edition published in 2000 (DMS-IV-TR) or the fifth edition published in 2013 (DSM-5).

[0023] In some embodiments of any of the above aspects of the disclosure, Compound I or Compound II is administered to the subject for a first treatment period of sufficient length to reduce the frequency and / or severity of at least one anxiety symptom. In an embodiment, the first treatment period is at least 2 weeks, at least 4 weeks, or at least 6 weeks. In an embodiment, the anxiety symptom is a physical symptom of anxiety, an emotional symptom of anxiety, a behavioral symptom of anxiety or a cognitive symptom of anxiety.

[0024] In some embodiments of any of the above aspects of the disclosure, if a subject experiences a reduction in at least one anxiety symptom during the first treatment period,

5

145084509 vl Attorney Docket No. : MNRV-015/001 WO then administration of the therapeutically effective dose of Compound I of Compound II is continued for a second treatment period of at least 12 weeks, at least 24 weeks, at least 48 weeks or until the subject is determined to be in remission from the anxiety disorder.

[0025] In some embodiments of any of the above aspects of the disclosure, the human subject is at least 18 years of age, while in other embodiments of any of the above aspects of the disclosure, the human subject is under 18 years of age.

[0026] In some embodiments of any of the above aspects of the disclosure, the human subject has not been previously treated with an anxiolytic drug. In other embodiments of any of the above aspects of the disclosure, the human subject has discontinued prior treatment with an anxiolytic drug due to experiencing an inadequate response and / or to intolerable side effects.

[0027] Other features and advantages of the disclosure will be apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] The foregoing summary, as well as the following detailed description, will be better understood when read in conjunction with the appended drawing.

[0029] Figure 1 is a graph showing mean changes from baseline in total HAM-A scores (y- axis) in a population of MDD patients treated over six weeks with once daily administration of placebo (solid), 2.5 mg MIN-117 (long dashes) or 0.5 mg MIN-117 (short dashes).

DETAILED DESCRIPTION

[0030] As described in the Examples set forth below, Compound I has been shown to have clinical activity in treating anxiety. Encompassed herein therefore are methods and compositions for treating various anxiety disorders.

[0031] U.S. Patent 6,720,320 discloses that a large number of phenoxypropylamine compounds and derivatives including Compound I and Compound II have selective affinity for and antagonistic activity against the 5-HTIA receptor, as well as 5-HT reuptake inhibitory activity. Based on this in vitro activity, U.S. Patent 6,720,320 hypothesized that all of these compounds would be useful as a rapid onset antidepressant and for the treatment of a number of 5-HT mediated diseases of the central nervous system, including anxiety neurosis, OCD, panic disorder, social anxiety disorder (social phobia) and PTSD. However, no animal model data for any of the disclosed compounds or diseases is contained in U.S. Patent 6,720,320. Notably, U.S. Patent 6,720,320 states that the general daily dose of the described

6

145084509 vl Attorney Docket No. : MNRV-015/001 WO phenoxypropylamine compounds in the case of oral administration is a weight based dose range of 0.5-10 mg/kg, preferably 1-5 mg/kg.

[0032] A published patent application (US2014-0206722) discloses the use of Compound I for treating or diminishing symptoms of depression, and teach that effective treatment of selected disorders can occur with oral dosing that approaches 0.001 mg/kg. However, the use of Compound I for treating anxiety or any anxiety disorder is not mentioned in US2014- 0206722.

[0033] It has now been unexpectedly observed that total oral daily doses of 0.5 mg and 2.5 mg of Compound I are capable of reducing the severity of one or more anxiety symptoms in patients diagnosed with MDD as measured on the HAMA-A scale, with the 0.5 mg dose demonstrating a more rapid reduction in the total HAMA-A score than the 2.5 mg dose. For purposes of reference, a 2.5 mg dose for a 70 kg subject equates to a weight-based dose of 0.036 mg/kg, which is more than 10 times lower than the lowest oral daily dose mentioned in U.S. Patent 6,720,320.

[0034] Thus, it is an object of the present disclosure to provide a method of treating at least one symptom of an anxiety disorder in a human subject diagnosed with the anxiety disorder comprising administering to the subject a therapeutically effective amount of a composition comprising Compound I or Compound II or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II.

[0035] It is also an object of the present disclosure to provide a composition comprising Compound I of Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, for use in a method for treating at least one symptom of an anxiety disorder in a human subject diagnosed with the anxiety disorder, wherein the method comprises administering to the subject a therapeutically effective amount of the composition.

[0036] It is a further object of the present disclosure to employ the compositions and methods of the disclosure to treat at least one symptom of an anxiety disorder in a human subject diagnosed with an anxiety disorder and with a co-morbid mental disorder, such as depression.

[0037] In embodiments, unless otherwise specified, Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate thereof is in an isolated form.

[0038] As used herein, the term "isolated" or the expression "in an isolated form" means substantially separated from other components with which the compound may be found as it occurs in nature. A compound can be isolated without necessarily being purified. In one embodiment, the isolated compound of formula I or II herein (or Compound I or Compound

145084509 vl Attorney Docket No. : MNRV-015/001 WO

II) is a synthesized compound. In another embodiment, Compound II is a metabolite and is isolated from other components with which the compound may be found as it occurs in a natural environment, e.g., cells of a mammal, e.g., a human or appropriate non-human mammal, such as primate, mouse, rat, dog, cat, cow, horse, goat, and camel. In

embodiments, the compounds or salts, hydrates, or solvates thereof disclosed herein each have a purity of not less than 40%, not less than 50%, not less than 55%, not less than 60%, not less than 65%, not less than 70%, not less than 75%, not less than 80%, not less than 85%, not less than 90%, not less than 92%, not less than 95%, not less than 97%, or not less than 99%.

[0039] As used herein, unless otherwise noted, the terms "treat", "treating", "treatment" and the like, shall include the management and care of a subject for the purpose of combating an anxiety disorder and include administration of Compound I or Compound II in an amount and for a treatment period that are sufficient to prevent the onset of one or more symptoms of an anxiety disorder, reduce the frequency, intensity or severity of one or more symptoms of an anxiety disorder, delay or avoid the development of additional symptoms, or any combination of these treatment objectives. In an embodiment, the effect of treatment with Compound I or Compound II is assessed by comparing the severity of the subject's anxiety at baseline (e.g., prior to treatment with Compound I or II) and after at least one treatment period. In an embodiment, the treatment period is at least one week, at least two weeks, at least four weeks, at least six weeks, at least eight weeks, or at least twelve weeks.

[0040] In an embodiment, the effect of the treatment is measured using the Hamilton Anxiety Scale (HAM-A). The HAM-A is composed of 14 items, each defined by a series of symptoms as shown in Table 1 below. The subject is asked to rate the gravity of each item using a 5-level scale - from 0 to 4, where 0 being not present and 4 being severe. The results are then collated and tabulated to determine the severity of anxiety: a HAM-A score of <17 is mild anxiety, HAM-A score of 18-24 is mild to moderate anxiety, and HAM-A score of 25- 30 is moderate to severe anxiety.

8

145084509 vl Attorney Docket No.: MNRV-015/001 WO

Table 1: Hamilton Anxiety Scale (HAM- A)

9

145084509 vl Attorney Docket No. : MNRV-015/001 WO

10

5084509 vl Attorney Docket No.: MNRV-015/001 WO

11

5084509 vl Attorney Docket No. : MNRV-015/001 WO

12

145084509 vl Attorney Docket No. : MNRV-015/001 WO

13

5084509 vl Attorney Docket No. : MNRV-015/001 WO

14

145084509 vl Attorney Docket No.: MNRV-015/001 WO

Total score

15

5084509 vl Attorney Docket No. : MNRV-015/001 WO

[0041] As used herein, the terms "subject" and "patient" may be used interchangeably, and refer to a human of any age. In an embodiment, the subject is six or more years of age. In some embodiments, the subject is at least 18, 19, 20 or 21 years of age. The subject is diagnosed with an anxiety disorder. In some embodiments, the subject is not diagnosed with another co-morbid mental disorder. In other embodiments, the subject is diagnosed with a co- morbid mental disorder. In some embodiments, the co-morbid mental disorder is a depression-related mood disorder.

[0042] In some embodiments, a composition or method of the disclosure is used to treat a subject diagnosed with an anxiety disorder who is treatment-naive to an anxiolytic drug. As used herein, an anxiolytic drug is any drug that does not contain Compound I or Compound II and has been approved by a regulatory agency for the treatment of anxiety or an anxiety disorder.

[0043] In other embodiments, a composition or method of the disclosure is used to treat a subject diagnosed with an anxiety disorder who was previously treated with an anxiolytic drug but discontinued such treatment, e.g., because the drug did not provide adequate control of the subject's anxiety symptoms and / or because the subject could not tolerate the side effects of the drug.

[0044] For purposes of the disclosure encompassed herein, the term "anxiety disorder" is to be understood as encompassing those conditions defined as anxiety disorders in the

Diagnostic and Statistical Manual of Mental Disorders, Fourth or Fifth Editions, published in 2000 ("DSM-IV-TR") and 2013 (DSM-5), respectively.

[0045] In an embodiment, the at least one symptom of an anxiety disorder that is treated using the compositions and methods of the present disclosure is selected from the group consisting of panic attacks, physical symptoms of anxiety, emotional symptoms of anxiety, behavioral symptoms of anxiety and cognitive symptoms of anxiety. As will be evident to the skilled artisan, a subj ect with one or more of these symptoms of anxiety would not typically be considered to have an anxiety disorder unless the symptom(s) reach a level of intensity, duration and frequency such that the symptoms cause significant distress to the subject and / or interfere with the subject's functioning.

[0046] In an embodiment, the anxiety disorder symptom is a panic attack, which is a sudden, extreme feeling of fear and/or discomfort lasting for a distinct period of time.

Typically, the subject will be diagnosed with a panic attack if the subject has at least 4 of the following symptoms: palpitations and/or pounding heart; sweating; trembling or shaking; shortness of breath or a sense of being smothered; feelings of choking; chest pain or

16

145084509 vl Attorney Docket No. : MNRV-015/001 WO discomfort, nausea; feeling dizzy, unsteady, lightheaded, or faint; hot flashes or chills;

numbness or tingling sensation; derealization (feelings of unreality), depersonalization (feeling detached from oneself); fear of losing control; and fear of dying. In some

embodiments, the subject suffers from unexpected (uncued) panic attacks, which do not have an identifiable source that triggers a panic attack. While in other embodiments, the subject suffers from expected (cued) panic attacks, i.e., attacks with an obvious cue or trigger.

[0047] In an embodiment, the anxiety disorder symptom is a physical symptom selected from the group consisting of: restlessness, shortness of breath, choking feeling, sweaty palms, racing heart, chest pain or discomfort, "butterflies" in the stomach, muscle tension, trembling, twitches, nausea, diarrhea, dizziness, feeling faint, hot flashes, chills, numbness, tingling sensations, an exaggerated startle response, headaches, sleep disturbance, and fatigue.

[0048] In an embodiment, the anxiety disorder symptom is an emotional symptom selected from the group consisting of: feelings of apprehension or dread, distress, dread, nervousness, feeling overwhelmed, panic, uneasiness, worry, fear or terror, jumpiness or edginess, irritability, and feeling like the mind has gone blank.

[0049] In an embodiment, the anxiety disorder symptom is a behavioral symptom of anxiety selected from the group consisting of: anxious avoidance, which refers to avoiding anxiety-producing situations (e.g., social gatherings) or places (e.g., using the stairs instead of an elevator); escaping from an anxiety -producing situation or place; sensitization, which is a coping strategy in which the subject seeks to learn about, rehearse, and/or anticipate fearful events; safety behaviors, in which the subject becomes overly attached to a safety object or person (e.g., refusing to go out, away from home, to school, or to work in order to avoid separation); engaging in unhealthy, risky or self-destructive behaviors (e.g., excessive drinking or drug use to deal with the anxiety); and feeling compelled to limit the amount and scope of one's daily activities to reduce the overall level of anxiety (e.g., remaining in the subject's home).

[0050] In an embodiment, the anxiety disorder symptom is a cognitive symptom of anxiety selected from the group consisting of: concentration problems (i.e., difficulty with staying on task); memory difficulties; and depressive symptoms (e.g., hopelessness, lethargy, poor appetite).

[0051] In an embodiment, a composition or method of the disclosure is used to treat a human subject diagnosed with generalized anxiety disorder (GAD). In an embodiment, and the symptom of GAD treated is selected from the group consisting of chronic worrying, a general feeling of dread or unease, feeling like the anxiety is uncontrollable, inability to

17

145084509 vl Attorney Docket No. : MNRV-015/001 WO tolerate uncertainty, nervousness, tension, insomnia, nausea, diarrhea, restlessness and fatigue.

[0052] In an embodiment, a composition or method of the disclosure is used to treat a human subject diagnosed with panic disorder, which is characterized by repeated, unexpected panic attacks, that are followed for at least a month by constant concerns about having more attacks and worrying about the consequences of the attacks.

[0053] In an embodiment, a composition or method of the disclosure is used to treat a human subject diagnosed with a phobia. In an embodiment, the phobia is agoraphobia, a specific phobia or social phobia (e.g., Social Anxiety Disorder). Typically, a subj ect must have symptoms that persist for at least 6 months to be diagnosed as having a phobia.

[0054] Exemplary symptoms of agoraphobia include intense fear, anxiety and avoidance of non-specific situations where escape of difficult or help might be unavailable if a panic attack occurs. Typically, a subject is diagnosed with agoraphobia if these symptoms occur in at least two of the following situations: using public transportation, being in open spaces, being in enclosed spaces, standing in line or being in a crowd, being outside of the home alone.

[0055] Exemplary symptoms of a specific phobia include intense fear, anxiety and avoidance of a specific object or situation that is out of proportion to any real danger posed by the object or situation, such as flying, heights, injections, animals.

[0056] Exemplary symptoms of social phobia include intense fear, anxiety and avoidance of social situations where there is the potential of being scrutinized or negatively judged by others.

[0057] In an embodiment, a composition or method of the disclosure is used to treat a human subject diagnosed with selective mutism, which is characterized by persistent refusal, typically for at least one month, to speak in specific situations where speaking is expected.

[0058] The compositions and methods of the disclosure may also be used to treat one or more symptoms of anxiety in a patient diagnosed with both an anxiety disorder and a depression-related mood disorder. In an embodiment, the depression related mood-related disorder is selected from the group consisting of major depressive disorder, persistent depressive disorder, depression associated with a bipolar disorder, dysthymic disorder, cyclothymic disorder, and substance-induced mood disorder.

[0059] The methods of the disclosure employ administering to the subject a therapeutically effective amount of Compound I or Compound II, or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or II. As used herein, the term "therapeutically effective amount" means an amount that is effective to reduce the presence and/or severity of at least

18

145084509 vl Attorney Docket No. : MNRV-015/001 WO one anxiety symptom by at least 10%, at least 20%, at least 40%, or at least 80% compared to baseline. Anxiety symptoms in the subject may be measured using any measurement tool generally accepted in the art, including but not limited to the HAM-A scale, the State-Trait Anxiety Inventory (STAI, available from Mind Garden, 855 Oak Grove Avenue, Suite 215, Menlo Park, CA 94025, http://www.rnindgarden.com/index.htm), the Beck Anxiety

Inventory (BAI, available at www.pearsonassessments.com), the Hospital Anxiety and Depression Scale-Anxiety (HADS-A, available from: Nfer Nelson, The Chiswick Centre, 414 Chiswick High Road, London W4 5TF United Kingdom, www.nfer-nelson.co.uk).

[0060] In some embodiments of the compositions and methods of the disclosure, the dose of Compound I or Compound II that is administered to a subject diagnosed with an anxiety disorder is effective to reduce the total HAMA-A score from baseline by at least 25%, at least 50%, or at least 75% after at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks or at least 6 weeks of treatment.

[0061] In yet another aspect of the disclosure, a composition of the disclosure is formulated and administered to the subject in a manner that provides a dose of Compound I or Compound II that is substantially equivalent to oral administration of any of the total daily doses specifically described herein. The skilled artisan can readily select formulations and administration routes that would provide such functional equivalence.

[0062] The disclosure also provides use of Compound I or Compound II or a

pharmaceutically acceptable salt, hydrate, solvate or polymorph thereof, in the manufacture of a medicament for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder. For example, the medicament is suitable for oral administration. For example, the medicament has a therapeutically effective amount of Compound I, which corresponds to a total daily dose of Compound I of between about 0.5 mg to about 2.5 mg.

[0063] It will be understood by the skilled artisan that the treating physician may select a dose and dosing regimen within the above guidelines that he or she believes is appropriate based on the health and condition of the subject to be treated, as well as the desired outcome of the treatment. For example, the treating physician may choose to start therapy with a lower than therapeutically effective dose of Compound I or Compound II and titrate up to a target therapeutically effective dose. For example, the total daily dose of Compound I or

Compound II may be administered in a single dose or in multiple doses.

[0064] As used herein, quantitative expressions recited as a range of from about value X to about value Y include any value that is 10% higher or lower than each of X and Y, and also

19

145084509 vl Attorney Docket No. : MNRV-015/001 WO includes any numerical value that falls between X and Y. Thus, for example, a dose of about 0.5 mg includes a dose of between 0.45 to 0.55 mg.

[0065] All references to Compound I and Compound II herein include all pharmaceutically acceptable salts and all solvates and alternative physical forms thereof unless otherwise states. All doses recited herein for Compound I are based on the weight of the free base of Compound I, rather than the pharmaceutically acceptable salt, hydrate of solvate thereof or any excipients in the composition, unless otherwise stated. Similarly, all doses recited herein for Compound II are based on the weight of the free base of Compound II, rather than the pharmaceutically acceptable salt, hydrate of solvate thereof or any excipients in the composition, unless otherwise stated. Further, all doses of Compound I or II recited herein are flat doses (e.g., not dependent on weight of the patient) unless otherwise stated.

[0066] For therapeutic administration according to the present disclosure, Compound I or Compound II may be employed in the form of its free base, but is preferably used in the form of a pharmaceutically acceptable salt. In an embodiment, the form of Compound I used in the compositions and methods of the disclosure is (2S)-l-[4-(3,4-dichlorophenyl)piperidin-l-yl]- 3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[/)]furan-4-yloxy]p ropan-2-ol monohydrochloride. In an embodiment, the form of Compound II used in the compositions and methods of the disclosure is (25 -l-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-hydroxymet hyl-l,3,4- oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride.

[0067] Compound (I) and Compound (II) may be synthesized using standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations, including the use of protective groups, as can be obtained from the relevant scientific literature or from standard reference textbooks in the field.

Although not limited to any one or several sources, recognized reference textbooks of organic synthesis include: Smith, M. B.; March, J. March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 ^th ed.; John Wiley & Sons: New York, 2001; and Greene, T.W.; Wuts, P.G. M. Protective Groups in Organic Synthesis, 3 ^rd ; John Wiley & Sons: New York, 1999. A method for preparing Compound (I) is described in U.S. Patent No. 6,720,320.

[0068] In an embodiment, alternative salts of Compound I or Compound II with pharmaceutically acceptable acids may also be utilized in therapeutic administration, for example salts derived from the functional free base and acids including, but not limited to, palmitic acid, hydrobromic acid, phosphoric acid, acetic acid, fumaric acid, maleic acid, salicylic acid, citric acid, oxalic acid, lactic acid, malic acid, methanesulfonic acid and p- toluene sulfonic acid.

20

145084509 vl Attorney Docket No. : MNRV-015/001 WO

[0069] All solvates and all alternative physical forms of Compound I, Compound II or their pharmaceutically acceptable derivatives as described herein, including but not limited to alternative crystalline forms, amorphous forms and polymorphs, are also within the scope of this disclosure, and all references to a compound of formula I or II herein (or Compound I or Compound II) include all pharmaceutically acceptable salts, and all solvates and alternative physical forms thereof.

[0070] For therapeutic administration, Compound I or Compound II, or a pharmaceutically acceptable salt of Compound I or II, for example, the HC1 salt, may be administered in pure form, but will preferably be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of the active ingredient in the body.

[0071] The term "pharmaceutically acceptable", as used herein with respect to a compound or composition, refers to a form of the compound or composition that can increase or enhance the solubility or availability of the compound in a subject, in order to promote or enhance the bioavailability of the compound or composition. In an embodiment, the disclosure herein also encompasses pharmaceutically acceptable, hydrates, solvates, stereoisomers, or amorphous solids of the compounds and compositions embodied herein. For example, the term

"pharmaceutically acceptable salt" is to describe a salt form of one or more of the compositions herein which are presented to increase the solubility of the compound, for example, in the gastric juices of the patient's gastrointestinal tract in order to promote dissolution and the bioavailability of the compounds and/or compositions. In an embodiment, pharmaceutically acceptable salts include those derived from pharmaceutically acceptable inorganic or organic bases and acids. Suitable salts include those derived from alkali metals such as potassium and sodium, alkaline earth metals such as calcium, magnesium and ammonium salts, among numerous other acids well known in the pharmaceutical art. Sodium and potassium salts are particularly preferred as neutralization salts of carboxylic acids and free acid phosphate containing compositions encompassed by the present disclosure. The term "salt" shall mean any salt consistent with the use of the compounds encompassed by the present disclosure. In the case where the compounds are used in pharmaceutical indications, including the treatment of depression, the term "salt" shall mean a pharmaceutically acceptable salt, consistent with the use of the compounds as pharmaceutical agents.

[0072] The term "pharmaceutically acceptable derivative" or "derivative", as used herein, describes any pharmaceutically acceptable prodrug form (such as an ester or ether or other prodrug group) which, upon administration to a patient, provides directly or indirectly the present compound or an active metabolite of the present compound.

21

145084509 vl Attorney Docket No. : MNRV-015/001 WO

[0073] As set forth above, the compositions include pharmaceutically acceptable salts of the compounds in the composition. In other embodiments, the acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned compounds are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate,

ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., Ι, Γ-methylene-bis- (2-hydroxy-3 naphthoate)] salts, among others.

[0074] In an embodiment, compositions comprise base addition salts of the present compounds. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of the present compounds that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine (meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines, among others.

[0075] As used herein, the term pharmaceutically acceptable salts or complexes refers to salts or complexes (e.g., solvates, polymorphs) that retain the desired biological activity of the parent compound and exhibit minimal, if any, undesired toxicological effects. Non- limiting examples of such salts are (a) acid addition salts formed with inorganic acids (for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, and the like), and salts formed with organic acids such as acetic acid, oxalic acid, tartaric acid, succinic acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, poly glutamic acid, naphthalenesulfonic acids, naphthalenedisulfonic acids, and

polygalacturonic acid; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, sodium, potassium, and the like, or with an organic cation formed from N,N- dibenzylethylene-diamine, ammonium, or ethylenediamine; or (c) combinations of (a) and (b); e.g., a zinc tannate salt or the like.

[0076] Modifications of a compound can affect the solubility, bioavailability and rate of metabolism of the active species, thus providing control over the delivery of the active species. Further, the modifications can affect the anxiolytic activity of the compound, in some

22

145084509 vl Attorney Docket No. : MNRV-015/001 WO cases increasing the activity over the parent compound. This can easily be assessed by preparing the derivative and testing its activity according to the methods encompassed herein, or other methods known to those skilled in the art.

[0077] In an embodiment, the compositions may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers and may also be administered in controlled-release formulations. Pharmaceutically acceptable carriers that may be used in these pharmaceutical compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as prolamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene- poly oxypropylene-block polymers, polyethylene glycol and wool fat.

[0078] Compositions encompassed herein may be administered orally. In other embodiments, compositions may be administered parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, percutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrastemal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. As will be understood by the skilled artisan, in view of the embodiments encompassed herein, the dosage of active ingredient or ingredients (e.g., a compound of formula I) may be adjusted upward or downward based on the selected route of

administration. Furthermore, it will be understood that optimizing the dosage of active ingredient for any selected dosage form may be desired and can be achieved by using the methods described herein or known in the art to evaluate the effectiveness of anxiolytic compounds.

[0079] The pharmaceutical compositions embodied herein may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. In an embodiment, lubricating agents, such as magnesium stearate, are also added. For oral administration in a capsule form, useful diluents include lactose and/or dried corn starch, as two non-limiting examples. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

23

145084509 vl Attorney Docket No. : MNRV-015/001 WO

[0080] The pharmaceutical compositions encompassed by the present disclosure may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[0081] In an embodiment, the therapeutically effective amount of Compound I is administered independently of any other medication that is indicated for the treatment of a mental disorder.

[0082] In another embodiment, the therapeutically effective amount of Compound I is administered in conjunction with one or more other medications to treat the anxiety disorder or to treat a co-morbid medical condition, including a depression-related mood disorder. Such other medications may be administered or co-administered in forms and dosages as known in the art, or in the alternative, as has been described above for administration of Compound I. The other medication(s) may be administered before, after or simultaneously with Compound

I during a desired treatment period.

[0083] In an embodiment, the therapeutically effective amount of Compound I may be administered to a patient diagnosed with a depression-related mood disorder and who is already undergoing treatment with an anti-depressant.

[0084] In an embodiment, the therapeutically effective amount of Compound II is administered independently of any other medication that is indicated for the treatment of a mental disorder.

[0085] In another embodiment, the therapeutically effective amount of Compound II is administered in conjunction with one or more other medications to treat the anxiety disorder or to treat a co-morbid medical condition, including a depression-related mood disorder. Such other medications may be administered or co-administered in forms and dosages as known in the art, or in the alternative, as has been described above for administration of Compound II. The other medication(s) may be administered before, after or simultaneously with Compound

II during a desired treatment period.

[0086] In an embodiment, the therapeutically effective amount of Compound II may be administered to a patient diagnosed with a depression-related mood disorder and who is already undergoing treatment with an anti-depressant.

[0087] In an embodiment, a compound set forth herein can be co-administered with one or more atypical antipsychotics. Examples of atypical antipsychotics include, but are not limited

24

145084509 vl Attorney Docket No. : MNRV-015/001 WO to fiuphenazine, risperidone, olanzapine, clozapine, quetiapine, ziprasidone, aripiprazole, sertindole, zotepine, and perospirone. Examples of antidepressants useful in combination therapy as encompassed herein include, but are not limited to, fluoxetine, citalopram, escitalopram, venlafaxine, duloxetine and bupropion.

Exemplary Embodiments

[0088] The present disclosure includes, but is not limited to, at least the following embodiments.

[0089] Embodiment 1 : a composition comprising a compound of formula I (Compound I)

or a compound of form la II (Compound II)

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, for use in a method for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder wherein the method comprises orally

administering to the subj ect a therapeutically effective amount of the composition, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

(i) about 0.1 mg to less than 3.0 mg;

25

145084509 vl Attorney Docket No. : MNRV-015/001 WO

(ii) about 0.2 mg to about 2.9 mg;

(iii) about 0.3 mg to about 2.8 mg;

(iv) about 0.4 mg to about 2.7 mg;

(v) about 0.5 mg to about 2.6 mg;

(vi) about 0.6 mg to about 2.5 mg,

(vii) about 0.4 mg to about 0.6 mg; and

(viii) about 0.5 mg.

[0090] Embodiment 2: the composition of embodiment 1, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

(i) about 0.25 mg to about 2.5 mg;

(ii) about 0.25 mg to about 1.5 mg;

(iii) about 0.25 to about 1.0 mg;

(iv) about 0.25 mg to about 0.75 mg;

(v) about 0.1 mg to about 2.0 mg;

(vi) about 0.1 mg to about 1.0 mg; and

(vii) about 0.1 mg to about 0.5 mg.

[0091] Embodiment 3: the composition of embodiment 1 or 2, which comprises about 0.5 mg of Compound I or Compound II.

[0092] Embodiment 4: the composition of any one of embodiments 1 to 3, wherein the composition comprises (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l -yl]-3-[2-(5-methyl-l ,3,4- oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride or (25)-l -[4-(3,4- dichlorophenyl)piperidin-l -yl]-3-[2-(5-hydroxymethyl-l,3,4-oxadiazol-2-yl)benzo[/)]fur an-4- yloxy]propan-2-ol monohydrochloride.

[0093] Embodiment 5: the composition of any one of embodiments 1 to 4, wherein the composition comprises (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l -yl]-3-[2-(5-methyl-l ,3,4- oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride.

[0094] Embodiment 6: a method of treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder, wherein the method comprises orally administering to the subject a therapeutically effective amount of a compound of formula I (Compound I),

26

145084509 vl Attorney Docket No.: MNRV-015/001 WO

or a compound of formula II (Compound II)

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or II, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

(i) about 0.1 mg to less than 3.0 mg;

(ii) about 0.2 mg to about 2.9 mg;

(iii) about 0.3 mg to about 2.8 mg;

(iv) about 0.4 mg to about 2.7 mg;

(v) about 0.5 mg to about 2.6 mg;

(vi) about 0.6 mg to about 2.5 mg,

(vii) about 0.4 mg to about 0.6 mg; and

(viii) about 0.5 mg.

[0095] Embodiment 7: the method of embodiment 6, wherein the therapeutically effective amount is selected from the group consisting of:

(i) about 0.25 mg to about 2.5 mg;

(ii) about 0.25 mg to about 1.5 mg;

(iii) about 0.25 to about 1.0 mg;

(iv) about 0.25 mg to about 0.75 mg;

27

145084509 vl Attorney Docket No. : MNRV-015/001 WO

(v) about 0.1 mg to about 1.0 mg;

(vi) about 0.1 mg to about 0.75 mg; and

(vii) about 0.1 mg to about 0.5 mg.

[0096] Embodiment 8: the method of embodiment 6 or 7, wherein the therapeutically effective amount is about 0.5 mg.

[0097] Embodiment 9: the method of any one of embodiments 6 to 8, wherein the form of Compound I administered is (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl- l,3,4-oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride.

[0098] Embodiment 10: use of a compound of formula I (Compound I)

or a compound of form la II (Compound II)

or a pharmaceutically acceptable salt, hydrate, or solvate of Compound I or Compound II, in the manufacture of a medicament for a method for treating at least one symptom of an anxiety disorder in a human subject who is diagnosed with the anxiety disorder wherein the method comprises orally administering to the subject a therapeutically effective amount of the composition, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

28

145084509 vl Attorney Docket No. : MNRV-015/001 WO

(i) about 0.1 mg to less than 3.0 mg;

(ii) about 0.2 mg to about 2.9 mg;

(iii) about 0.3 mg to about 2.8 mg;

(iv) about 0.4 mg to about 2.7 mg;

(v) about 0.5 mg to about 2.6 mg;

(vi) about 0.6 mg to about 2.5 mg,

(vii) about 0.4 mg to about 0.6 mg; and

(viii) about 0.5 mg.

[0099] Embodiment 11 : the use of embodiment 10, wherein the therapeutically effective amount is a total daily dose of Compound I or Compound II selected from the group consisting of:

(i) about 0.25 mg to about 2.5 mg;

(ii) about 0.25 mg to about 1.5 mg;

(iii) about 0.25 to about 1.0 mg;

(iv) about 0.25 mg to about 0.75 mg;

(v) about 0.1 mg to about 2.0 mg;

(vi) about 0.1 mg to about 1.0 mg; and

(vii) about 0.1 mg to about 0.5 mg.

[00100] Embodiment 12: the use of embodiment 10 or 11 , which comprises about 0.5 mg of Compound I or Compound II.

[00101] Embodiment 13 : the use of any one of embodiments 10 to 12, wherein the composition comprises (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l -yl]-3-[2-(5-methyl-l ,3,4- oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride or (25 -l -[4-(3,4- dichlorophenyl)piperidin-l -yl]-3-[2-(5-hydroxymethyl-l,3,4-oxadiazol-2-yl)benzo[/)]fur an-4- yloxy]propan-2-ol monohydrochloride.

[00102] Embodiment 14: the use of any one of embodiments 10 to 13, wherein the composition comprises (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l -yl]-3-[2-(5-methyl-l ,3,4- oxadiazol-2-yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride.

[00103] Embodiment 15 : the composition, method, or use of any one of embodiments 1 to 14, wherein the subject has been diagnosed with a co-morbid mental disorder.

[00104] Embodiment 16: the composition, method, or use of embodiment 15, wherein the co-morbid mental disorder is a depression-related mood disorder.

[00105] Embodiment 17: the composition, method, or use of embodiment 16, wherein the co-morbid mental disorder is Major Depressive Disorder.

29

145084509 vl Attorney Docket No. : MNRV-015/001 WO

[00106] Embodiment 18: the composition, method, or use of any one of embodiments 1 to

14, wherein the subject has not been diagnosed with a co-morbid mental disorder.

[00107] Embodiment 19: the composition, method, or use of any one of embodiments 1 to

18, wherein the anxiety disorder is selected from the group consisting of: Separation Anxiety Disorder, Selective Mutism, Specific Phobia, Social Anxiety Disorder (Social Phobia), Panic

Disorder, Panic Attack Specifier, Agoraphobia, Generalized Anxiety Disorder,

Substance/Medication-Induced Anxiety Disorder, Anxiety Disorder Due to Another Medical Condition, Other Specified Anxiety Disorder, Unspecified Anxiety Disorder, Obsessive- Compulsive Disorder, Body Dysmorphic Disorder, Hoarding Disorder, Trichotillomania (Hair-Pulling Disorder), Excoriation (Skin-Picking) Disorder, Substance/Medication-Induced Obsessive-Compulsive and Related Disorder, Obsessive-Compulsive and Related Disorder Due to Another Medical Condition, Other Specified Obsessive-Compulsive and Related Disorder, Unspecified Obsessive-Compulsive and Related Disorder, Reactive Attachment Disorder, Disinhibited Social Engagement Disorder, Posttraumatic Stress Disorder, Acute Stress Disorder, Adjustment Disorders, Other Specified Trauma- and Stressor-Related Disorder, Unspecified Trauma- and Stressor-Related Disorder.

[00108] Embodiment 20: the composition, method, or use of any one of embodiments 1 to

19, wherein the anxiety disorder diagnosis is based on the criteria set forth in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric

Association (DSM).

[00109] Embodiment 21 : the composition, method, or use of any one of embodiments 1 to

20, wherein the at least one anxiety symptom is a physical symptom of anxiety, an emotional symptom of anxiety, a behavioral symptom of anxiety or a cognitive symptom of anxiety.

[00110] Embodiment 22: the composition, method, or use of any one of embodiments 1 to 21, wherein the treating is conducted for a first treatment period selected from the group consisting of at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks and at least 6 weeks.

[00111] Embodiment 23: the composition, method, or use of embodiment 22, wherein if the first treatment period results in reduction of the at least one anxiety symptom in the subject, then the treating is continued for a second treatment period selected from the group consisting of at least 12 weeks, at least 24 weeks, and at least 48 weeks.

[00112] Embodiment 24: the composition, method, or use of any one of embodiments 1 to 23, wherein the human subject has not been previously treated with an anxiolytic drug.

30

145084509 vl Attorney Docket No. : MNRV-015/001 WO

[00113] Embodiment 25 : the composition, method, or use of any one of embodiments 1 to 23, the human subject has discontinued prior treatment with an anxiolytic drug due to experiencing an inadequate response and / or to intolerable side effects.

[00114] Embodiment 26: the composition, method, or use of any one of embodiments 1 to 25, wherein the human subject is diagnosed with MDD and (2S)-l -[4-(3,4- dichlorophenyl)piperidin-l -yl]-3-[2-(5-methyl-l ,3,4-oxadiazol-2-yl)benzo[/)]furan-4- yloxy]propan-2-ol monohydrochloride is co-administered with an anti-depressant that does not comprise Compound I or Compound II.

[00115] Embodiment 27: the composition, method, or use of any one of embodiments 1 to 25, wherein (2S)-l -[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l ,3,4-oxadiazol-2- yl)benzo[Z>]furan-4-yloxy]propan-2-ol monohydrochloride is co-administered with one or more atypical antipsychotics.

[00116] Embodiment 28: the composition, method, or use of any one of embodiments 1 to 27, wherein the total daily dose of Compound I is administered in a single dose.

[00117] Embodiment 29: the composition, method, or use of any one of embodiments 1 to 27, wherein the total daily dose of Compound I is administered in multiple doses, e.g., twice daily or three or four times daily.

[00118] Embodiment 30: the composition, method, or use of any one of embodiments 1 to 27, wherein the total daily dose of Compound II is administered in a single dose.

[00119] Embodiment 31 : the composition, method, or use of any one of embodiments 1 to 27, wherein the total daily dose of Compound II is administered in multiple doses, e.g., twice daily or three or four times daily.

[00120] The embodiments encompassed herein are now described with reference to the following Examples. These Examples are provided for the purpose of illustration only and the disclosure encompassed herein should in no way be construed as being limited to these

Examples, but rather should be construed to encompass any and all variations which become evident as a result of the teachings provided herein.

EXAMPLES

[00121] Example 1. MIN-1 17 reduces anxiety symptoms in patients diagnosed with MDD.

[00122] A phase 2a, multicenter, multinational, randomized, double-blind, placebo- and active-controlled parallel-group study was conducted to investigate the efficacy and safety of MIN-117 in adult subj ects with MDD. One of the exploratory objectives of the study was to

31

145084509 vl Attorney Docket No. : MNRV-015/001 WO assess effects of MIN-117 compared to placebo on anxiety as measured by change from baseline in the Hamilton Anxiety Rating Scale (HAM- A) over 6 weeks of treatment.

[00123] The study consisted of a 4-week pre-treatment phase during which subjects were washed out from antidepressant medications or other psychotropics, followed by a 6-week treatment phase, and then an end of study (EOS) follow-up visit at approximately 2-weeks after the end of the treatment phase. MIN-117 capsules of 0.5 mg and 2.5 mg strength were used in the study. The capsules were size 4 made of white hard gelatin containing the drug substance, lactose, cornstarch, low substituted hydroxypropylcelullose and

hydroxypropylcelullose, and purified water.

[00124] Eighty-four eligible subjects (met the DSM-5 diagnostic criteria for moderate to severe MDD, without psychotic features) were randomized in a 1 : 1 : 1 : 1 ratio, to receive once daily oral doses of placebo, MIN-117 at 0.5 mg, MIN-117 at 2.5 mg, or paroxetine at 20 mg as an active comparator for 6 weeks. Paroxetine is an antidepressant of the SSRI class and is used to treat MDD, OCD, PTSD, social anxiety disorder, panic disorder, GAD, premenstrual dysphoric disorder and menopausal hot flashes. The HAM-A scale was used to measure the severity of each subject's anxiety at screening, baseline, and weeks 1, 2, 4, 6 (or early withdrawal) and EOS.

[00125] The Inclusion and Exclusion Criteria for the study are set forth below.

Inclusion Criteria

Subjects had to meet all of the following inclusion criteria to be eligible for participation in this study:

1. Subjects must be able to read and understand the consent forms, complete study-related procedures, and communicate with the study staff.

2. Subjects must have provided written consent to participate in the study and understand that they are free to withdraw from the study at any time.

3. Male or female subjects must be 18 to 65 years of age, inclusive, at Screening (Visit 1).

4. Subjects have a body mass index (BMI) of > 18 to≤ 35 kg/m ² [BMI = weight (kg)/height (m ² )] at Screening (Visit 1)

5. Subjects must meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for diagnosis of moderate or severe depression without psychotic features (ICD-9 codes 296.32 & 296.33; ICD-10 codes F33.1 & F33.2, respectively) at Screening based on clinical assessment and on the MINI, v7.0.

6. Subjects have a history of at least one previous episode of depression prior to the current episode.

32

145084509 vl Attorney Docket No. : MNRV-015/001 WO

7. Current major depressive episode of at least 8 weeks in duration.

8. Subjects must have a score of > 30 on the investigator-rated MADRS at Screening (Visit 1) and Baseline (Visit 2a).

9. Subjects must have a score of > 4 on the investigator-rated CGI-S at Screening (Visit 1) and Baseline (Visit 2a).

10. Subjects must be in good general health prior to study participation with no clinically relevant abnormalities as assessed by the investigator and determined by medical history, physical examination, blood chemistry, hematology, urinalysis, and electrocardiogram (ECG).

11. Female subj ects must be postmenopausal, have had a hysterectomy or tubal ligation or be otherwise incapable of pregnancy, or must agree to consistent use of 2 approved methods of contraception for the duration of the study (oral or parenteral hormonal contraceptive or intrauterine device or barrier plus spermicide) and until 90 days after the last dose of the study treatment.

12. Male subjects who are willing to use condom for the duration of the study and until 90 days after the last dose of the study, even if they have had vasectomy, and must inform their partners about taking an investigational medication. Female partners of subjects who have not had vasectomy must also agree to use an approved method of contraception until 90 days after the last dose of the study treatment.

Exclusion Criteria

Subjects who met any of the following criteria were to be excluded from participating in this study:

1. A DSM-5 diagnosis of current (active) obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), anorexia nervosa, or bulimia nervosa.

2. Significant past or present neurological or neurosurgical disorder that could interfere with the study assessments (including but not limited to stroke, central nervous system [CNS] -related tumors, multiple sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, seizure disorder requiring current anticonvulsants, history of brain injury or trauma, or neurosyphilis).

3. History or current diagnosis of schizophrenia or any psychotic disorder, bipolar disorder, mental retardation, or cluster B personality disorders, mood disorder with postpartum onset, somatoform disorders, chronic fatigue syndrome, or fibromyalgia.

33

145084509 vl Attorney Docket No. : MNRV-015/001 WO Meeting DSM-5 criteria for substance abuse (alcohol or drugs) within 12 months prior to Screening Visit or substance dependence (except nicotine and caffeine) within 6 months prior to the Screening Visit or positive test for drugs of abuse.

Moderate or high risk of violent behavior or suicide as assessed by any history of suicide attempt, or a score of > 4 on MADRS item 10.

History of inadequate treatment response on 2 or more occasions of treatment with approved antidepressants (paroxetine included) as defined by failure to improve when treated with a licensed dose for an adequate duration.

History of treatment with electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), vagus nerve stimulation (VNS), or any related neuromodulator therapy within 6 months prior to the Screening Visit, including light therapy.

Subjects who, in the opinion of the investigator, should not discontinue, or participate in washout of a prohibited concomitant medication.

Receiving psychological treatments (e.g., cognitive behavior therapy, interpersonal psychotherapy, or psychodynamic psychotherapy) other than psychoeducational within

1 week prior to Baseline Visit (randomization) that has not remained constant for at least 3 months, or that may change during this study.

Significant past or present metabolic, hepatic (including > 3X upper limit of normal [ULN] in liver function test at Screening and Baseline), renal, hematological, pulmonary, cardiovascular, metabolic, gastrointestinal, or urological disorder.

Any history of drug or other significant allergy or known hypersensitivity to any of the study drugs.

History of malignant disease within the past 5 years with the exception of minor superficial skin diseases (i.e., basal cell carcinoma and squamous cell carcinoma).

Any medical condition that can potentially alter oral enteral absorption (e.g., gastrectomy), metabolism (e.g., liver failure), or excretion (e.g., renal failure) of the study drug.

Hypothyroidism or hyperthyroidism, unless stabilized by appropriate medication for at least 3 months prior to Screening (a normal thyroid-stimulating hormone [TSH] is required at Screening).

Pregnant or breast-feeding femal e.

Experimental drug use or experimental medical device use within 6 months before the planned start of treatment (Day 1).

34

509 vl Attorney Docket No. : MNRV-015/001 WO

17. Positive hepatitis B surface antigen (HBsAg), or hepatitis C antibody, or human

immunodeficiency virus (HIV) 1 and 2 antibodies at Screening.

18. Subjects with a clinically significant electrocardiogram (ECG) abnormality at Screening or Baseline visits that could be a safety issue in the study, including QT interval value corrected for heart rate using the Fridericia's formula (QTcF) > 430 msec for males and > 450 msec for females.

19. Employees of the investigator or study center, when the employee has direct

involvement in the proposed study or other studies under the direction of that investigator or study center; also family members of the employee or the investigator.

20. No legal capacity or limited legal capacity or unable to give an informed consent.

21. Subjects unlikely to cooperate in the study, and/or poor compliance anticipated by the investigator.

[00126] A summary of the demographic characteristics of the patients assigned to each arm of the study is shown in Table 2 below.

Table 2: Demography

[00127] The change in HAM-A scores from baseline at weeks 1, 2, 4 and 6 weeks of treatment with placebo or a study drug are shown in Figure 1. As shown in Figure 1, each of the study drugs exhibited a reduction in the severity of anxiety symptoms compared to placebo in the intent to treat population (ITT) as measured by HAM-A scale over the course

35

145084509 vl Attorney Docket No. : MNRV-015/001 WO of the study, with patients treated with the 0.5 mg dose of MIN-117 exhibiting the fastest onset of this beneficial effect (compare Week 1 vs. Week 2 for all four arms). By Week 6, both doses of MIN-117 appeared to be comparable in terms of their ability to reduce the severity of the symptoms. Treatment with MIN-117 at both doses was well tolerated.

[00128] Although the study was not powered to achieve statistical significance, these results indicate that MIN-117 is capable of reducing the severity of one or more anxiety symptoms at total daily doses of 0.5 mg or 2.5 mg, with the 0.5 dose achieving a beneficial result over placebo as early as 2 weeks after starting therapy.

36

145084509 vl Attorney Docket No. : MNRV-015/001 WO

EQUIVALENTS AND INCORPORATION BY REFERENCE

[00129] The invention has been described herein by reference to certain preferred embodiments. However, as particular variations thereon will become apparent to those skilled in the art, based on the disclosure set forth herein, the invention is not to be considered as limited thereto.

[00130] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. In the specification and claims, the singular forms also include the plural unless the context clearly dictates otherwise.

[00131] It is to be understood that at least some of the descriptions of the invention have been simplified to focus on elements that are relevant for a clear understanding of the invention, while eliminating, for purposes of clarity, other elements that those of ordinary skill in the art will appreciate may also comprise a portion of the invention. However, because such elements are well known in the art, and because they do not necessarily facilitate a better understanding of the invention, a description of such elements is not provided herein.

[00132] Further, to the extent that the method does not rely on the particular order of steps set forth herein, the particular order of the steps should not be construed as limitation on the claims. The claims directed to the method of the present disclosure should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the steps may be varied and still remain within the spirit and scope of the present disclosure.

[00133] All patents, patent applications, references and publications cited herein are fully and completely incorporated by reference as if set forth in their entirety.

37

145084509 vl